• Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Three years of long-acting release octreotide (octreotide LAR) significantly reduced liver volume in patients with polycystic kidney and liver disease, researchers found in a placebo-controlled study. These reductions, reported in the July issue of Clinical Gastroenterology and Hepatology, were maintained for 2 years after treatment ended. Polycystic liver disease (PLD)

Read more

Can Imaging Identify the Most Dangerous Pancreatic Cystic Neoplasms?

Endoscopic ultrasound can be used to identify cystic neoplasms of the pancreas that are most likely to become malignant, according to the February issue of Clinical Gastroenterology and Hepatology. Mucus-producing cystic neoplasms of the pancreas, including intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN), that have mural nodules

Read more